Keyphrases
Vault
100%
β-Galactosidase (β-Gal)
83%
Magnetic Particles
66%
Mammalian Cells
64%
α-galactosidase
63%
Lysosomal Storage Disease
56%
Fabry Disease
53%
Cell Factory
52%
Recombinant
51%
Secretory Granules
44%
Granules
41%
Recombinant Protein
40%
Human Cells
38%
Nanoparticles
38%
Biofabrication
37%
Plasmid DNA (pDNA)
33%
Less Is More
33%
Fast Production
33%
Advanced Cell Therapy
33%
DNA Concentration
33%
Bioactive Proteins
33%
Liposomal
33%
Quality by Design
33%
Delos
33%
Recombinant Cells
33%
Highly Stable
33%
Biosafety
33%
Sustained Release
33%
Enzymatic Characterization
33%
Nanomilling
33%
Functional Inclusion Bodies
33%
Inclusion Bodies
33%
Extracellular Vesicles
33%
Novel Therapies
33%
Targeted Drug Delivery
33%
Escherichia Coli
33%
Aggresome
33%
Protocol Optimization
33%
New Platform
33%
Virus-neutralizing Antibody
33%
Soluble Protein
33%
SARS-CoV-2 Spike Protein
33%
Zinc
33%
Antibody Response
33%
Micron-scale
33%
Cell Penetration
33%
Tolerability
33%
Endosomal
33%
Enzyme Replacement Therapy
31%
Receptor-binding Domain
27%
Pharmacology, Toxicology and Pharmaceutical Science
SARS Coronavirus
83%
Galactosidase
66%
Protein
66%
Receptor
66%
Subcutaneous Injection
66%
Fabry Disease
58%
Drug Delivery System
58%
Lysosome Storage Disease
56%
Recombinant Protein
52%
Secretory Protein
50%
Infection
50%
Alpha Galactosidase
44%
Storage Disease
41%
Replacement Therapy
36%
Sustained Release
33%
Drug Release
33%
Virus Antibody
33%
Protein Aggregate
33%
Targeted Drug Delivery
33%
Microparticle
33%
Histidine
33%
Polypeptide
33%
Virus Infection
33%
Adjuvant
33%
Subcutaneous Route
33%
Protein Delivery
25%
Nanoparticle
24%
Disease
19%
Antibodies
16%
N Sulfoglucosamine Sulfohydrolase
16%
Bioavailability
16%
Subunit Vaccine
16%
Bacterial Infection
16%
Antitumor Activity
16%
Polypeptide Antibiotic Agent
16%
Amyloid Protein
16%
Diseases
16%
Intranasal Route
16%
Viral Clearance
16%
Syrian Hamster
16%
Globotriaosylceramide
14%
Pharmacological Chaperone
13%
Lung Resistance Protein
13%
Degenerative Disease
11%
Cosmetics
8%
Enzyme Deficiency
8%
Cerebrovascular Disease
8%
Pharmaceutical Manufacturing
8%
Preclinical Study
8%
Recombinant Enzyme
8%
